Bozhou TCM Exports Surge: 50 Countries Reached, Market Impact Deepens

Bozhou (亳州, Bózhōu), the “Capital of Traditional Chinese Medicine” (中药之都, zhōngyào zhī dū) in Anhui Province, has expanded its export reach to 50 countries as of August 2025, with total export value surpassing 12.3 billion yuan in the first six months of the year — a 24% increase compared to the same period in 2024. This milestone positions Bozhou as the primary gateway for traditional Chinese medicine (TCM, 中医药, zhōngyī yào) raw materials and finished products entering international markets across Asia, Europe, Africa, and the Americas.

In 2019, Bozhou’s TCM exports reached just 32 countries with a total value of 7.8 billion yuan. By 2022, the count rose to 41 countries, and the current 50-country footprint represents a 56% increase in geographic coverage over six years. Export shipments to Belt and Road Initiative (一带一路, yī dài yī lù) countries now account for 62% of total value, up from 48% in 2020. The average export price per ton has also risen to 18,900 yuan, reflecting a structural shift toward higher-value processed forms such as concentrated granules and patented formulas.

Export Growth Trajectory: From Regional Hub to Global Exporter

Bozhou’s rise as a TCM export powerhouse is rooted in centuries-old trading tradition and modern industrial upgrades. The city operates the largest TCM wholesale market in China, covering 1.2 million square meters with over 6,000 varieties of medicinal herbs. In 2024, the market handled 38 billion yuan in transactions, with an export component of 14.5 billion yuan directly shipped to overseas buyers. More than 1,800 of Bozhou’s 4,200 registered herb-processing enterprises now hold export licenses, up from 760 in 2019.

The expansion to 50 countries has been driven by two supply-side factors: standardized production facilities that meet international pharmacopoeia standards, and aggressive trade promotion through exhibitions such as the International (Bozhou) TCM Expo, which attracted over 1,200 foreign buyers in 2025. Companies like Bozhou Huayuan Pharmaceutical and Anhui Longzhiyuan have obtained Good Manufacturing Practice (良好生产规范, liánghǎo shēngchǎn guīfàn) certifications verified through third-party audits, enabling access to regulated markets like Australia and the European Union.

Key Export Destinations and Demand Drivers

The top five importers of Bozhou TCM products in 2024 were Japan (2.8 billion yuan), South Korea (2.1 billion yuan), Germany (1.3 billion yuan), the United States (1.1 billion yuan), and Vietnam (890 million yuan). Japan and South Korea together account for 33% of total exports, primarily sourcing raw herbs and extracts for their domestic Kampo (汉方, hànfāng) and Hanbang (韩方, hánfāng) industries. Demand from Africa and Latin America has grown rapidly, with shipments to Nigeria and Brazil increasing 41% and 38% respectively year-over-year, driven by interest in affordable antimicrobial and anti-malarial preparations.

The table below summarizes Bozhou’s top export destinations and their import profiles:

Market Impact: Pricing, Supply Chains, and Quality Standards

The broader export push has lifted the local market. Since 2023, prices for key raw herbs such as Scutellaria baicalensis (黄芩, huángqín) and Poria cocos (茯苓, fúlíng) have risen 18% and 25% respectively, driven by international demand outpacing domestic supply. This has benefited Bozhou’s growers and processors, but also created price volatility for Chinese hospitals and domestic pharmacies — spot prices for 黄芩 fluctuated by as much as 21% between the first and fourth quarters of 2024.

Foreign buyers are increasingly requiring organic certification (有机认证, yǒujī rènzhèng) and heavy-metal testing reports. In response, Bozhou’s city government invested 360 million yuan in a dedicated TCM quality inspection and traceability center, which now issues digital certificates accepted in 35 countries. Residue limits for export batches are set at 50% of China’s national standard, reflecting a stricter baseline demanded by international pharmacopoeias. A 2024 audit by the EU Directorate-General for Health found that 91% of Bozhou’s sample shipments met European Pharmacopoeia standards, up from 74% in 2020.

Outlook and Regulatory Considerations for Foreign Buyers

As Bozhou pushes toward 60 destination countries by 2026, foreign executives must monitor evolving regulatory requirements. In 2024 alone, three new EU directives on botanicals and two USDA import alerts directly affected Bozhou shipments, leading to 19 containers held at customs for additional testing. The city’s TCM Trade Promotion Association (中医药贸易促进会, zhōngyī yào màoyì cùjìn huì) has established a dedicated compliance desk to assist exporters with documentation — including certificates of origin, phytosanitary certificates, and product registration files — reducing clearance delays by an average of 11 days per shipment.

For buyers, the key takeaway is that Bozhou’s supply is resilient but increasingly tied to compliance cost. The window for sourcing at lowest cost is narrowing, while investment in traceability and third-party certification yields a premium product that commands higher margins. The market impact of this 50-country expansion is twofold: more availability of standardized TCM globally, and a gradual shift toward quality premiums that favor long-term sourcing partnerships over spot purchases.

NEXT STEPS

1. Audit your supply chain: Before placing large orders, conduct a Bozhou supplier audit using our Bozhou Supplier Audit Checklist — covers certifications, pricing transparency, and export capacity documentation.
2. Review compliance requirements: Each of the 50 destination countries has unique entry rules; our TCM Import Regulations comparison walks through documentation needs for the top 10 markets.
3. Plan a sourcing trip: See our Bozhou Herb Market Overview for recommendations on reliable trading floors, translators, and logistics partners.

— Anhui Gateway —
Remote China market entry support, built around execution.